Abstract
The purpose of this research was to develop mouth dissolve tablets of nimesulide. Granules containing nimesulide, camphor, crospovidone, and lactose were prepared by wet granulation technique. Camphor was sublimed from the dried granules by exposure to vacuum. The porous granules were then compressed. Alternatively, tablets were first prepared percentage friability, wetting time, and disintegration time. In the investigation, a 32 full factorial design was used to investigate the joint influence of 2 formulation variables: amount of camphor and crospovidone. The results of multiple linear regression analysis revealed that for obtaining a rapidly disintegrating dosage form, tablets should be prepared using an optimum concentration of camphor and a higher percentage of crospovidone. A contour plot is also presented to graphically represent the effect of the independent variables on the disintegration time and percentage friability. A checkpoint batch was also prepared to prove the validity of the evolved mathematical model. Sublimation of camphor from tablets resulted in superior tablets as compared with the tablets prepared from granules that were exposed to vacuum. The systematic formulation approach helped in understanding the effect of formulation processing variables.
Keywords: mouth dissolve tablet, nimesulide, camphor, factorial design, contour plot
Full Text
The Full Text of this article is available as a PDF (156.8 KB).
References
- 1.Chang R, Guo X, Burnside B, Couch R. A review of fast dissolving tablets.Pharm Tech. (North America). June, 2000:52–58.
- 2.Bi Y, Sunada H, Yonezawa Y, Dayo K, Otsuka A, Iida K. Preparation and evaluation of a compressed tablet rapidly disintegrating in oral cavity. Chem Pharm Bull (Tokyo) 1996;44:2121–2127. doi: 10.1248/cpb.44.2121. [DOI] [PubMed] [Google Scholar]
- 3.Corveleyn S, Remon JP. Formulation and production of rapidly disintegrating tablets by lyophilization using hydrochlorthiazide as a model drug. Int J Pharm. 1997;152:215–225. doi: 10.1016/S0378-5173(97)00092-6. [DOI] [Google Scholar]
- 4.Remon JP, Corveleyn S. Freeze-dried rapidly disintegrating tablets. US patent 6 010 719. January 4, 2000.
- 5.Heinemann H, Rothe W. Preparation of porous tablets. US patent 3 885 026. May 20, 1975.
- 6.Knistch A, Hagen E, Munz HD. Production of porous tablets. US patent 4 134 843, January 16, 1979.
- 7.Roser BJ, Blair J. Rapidly soluble oral dosage forms, method of making same, and composition thereof. US patent 5 762 961. June 9, 1998.
- 8.Wallace JL. Prostaglandins, NSAIDs and cytoprotection. Gastroenterol Clin. North Am. 1992;21:631–641. [PubMed] [Google Scholar]
- 9.Singla AK, Chawla M, Singh A. Nimesulide: some pharmaceutical and pharmacological aspects and update. J Pharm Pharmacol. 2000;52:467–486. doi: 10.1211/0022357001774255. [DOI] [PubMed] [Google Scholar]
- 10.Dapino P, Ottonello L, Dallegri F. The anti-in flammatory drug nimesulide inhibits neutrophil adherence to and migrations across monolayers of cytokine-activated endothelial cells. Respiration. 1994;61:336–341. doi: 10.1159/000196365. [DOI] [PubMed] [Google Scholar]
- 11.Piel G, Pirotte I, Delnevvile I, Neven P, Delattre L. Study of the influence of both cyclodextrin and L-lysine on the aqueous solubility of Nimesulide: isolation and characterization of nimesulide L-lysine-cyclodextrin complexes. J Pharm Sci. 1997;86:475–480. doi: 10.1021/js960298k. [DOI] [PubMed] [Google Scholar]
- 12.Nalluri BN, Chowdary KPR, Murthy KVR, Hayman AR, Becket G. Physicochemical characterization and dissolution properties of nimesulide-cyclodextrin binary systems. AAPS PharmSciTech. 2003;4(1):E2–E2. doi: 10.1208/pt040102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Seedher N, Bhatia S. Solubility enhancement of cox-2 inhibitors using various solvent systems. AAPS PharmSciTech. 2003;4(3):E33–E33. doi: 10.1208/pt040333. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Bolton S. Pharmaceutical Statistics. 2nd ed. New York, NY: Marcel Decker Inc; 1990. pp. 234–234. [Google Scholar]
- 15.Franz RM, Browne JE, Lewis AR. Experiment design, modeling and optimization strategies for product and process development. In: Libermann HA, Reiger MM, Banker GS, editors. Pharmaceutical Dosage Forms: Disperse Systems. New York, NY: Marcel Dekker Inc; 1988. pp. 427–519. [Google Scholar]
- 16.Koizumi K, Watanabe Y, Morita K, Utoguchi N, Matsumoto M. New method of preparing high porosity rapidly saliva soluble compressed tablets using mannitol with camphor, a subliming material. Int J Pharm. 1997;152:127–131. doi: 10.1016/S0378-5173(97)04924-7. [DOI] [Google Scholar]
- 17.Kornblum S, Stoopak S. A new tablet disintegrating agent: cross-linked polyvinylpyrollidone. J Pharm Sci. 1973;62:43–49. doi: 10.1002/jps.2600620107. [DOI] [PubMed] [Google Scholar]
- 18.Shasaku K. Fast disintegrating solid formulations of aniretam. Jpn Kokai Tokyo Koho. Japanese patent 11 13 662. May 15, 1999.
- 19.Mendenhall W, Sincich T. A Second Course in Business Statistics, Regression Analysis. 3rd ed. San Francisco, CA: Dellen Publishing Co; 1989. Multiple regression; pp. 141–226. [Google Scholar]